Value-Based Cancer Care Issues

October 2016, Vol 7, No 9

Immunotherapy Moving into Prime Time

Nick Bryant


New York, NY—At the Second International Cancer Immunotherapy Conference: Translating Science into Survival, immunotherapy pioneer Philip Greenberg, MD, Head, Immunotherapy Program, Fred Hutchison Cancer Research Center, Seattle, moderated a press discussion with several of the immunotherapy experts who presented at [ Read More ]

Value Propositions – October 2016

Value Propositions

In This Article Melanoma Tumors Use Genetic Mutations to Resist Ipilimumab NCCN Imaging Appropriate Use Criteria Incorporated into New Century Health’s Clinical Support Platform MD Anderson Cancer Center Awarded $19 Million for Funding, Recruitment Using CAR T-Cells as Targeted Delivery [ Read More ]

FDA News – October 2016

FDA Approvals, News & Updates

In This Article Dosage Regimen for Nivolumab Modified Use of Screening Tests for Ovarian Cancer Not Supported by the FDA Dosage Regimen for Nivolumab Modified On September 13, 2016, the FDA modified the dosage regimen of nivolumab (Opdivo) for the treatment of patients with renal-cell carcinoma, metastatic melanoma, and non–small-cell lung cancer (NSCLC) to 240 mg intravenously (IV) every [ Read More ]

In the Literature – October 2016

In the Literature

In This Article Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma Addition of Elective Neck Dissection Reduces Overall Costs in Patients with Oral Cavity Cancer 70-Gene Signature Assists Clinicians in Breast Cancer Treatment Decision-Making Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Many patients with B-cell acute lymphoblastic leukemia (ALL) who achieve complete remission will have disease relapse. Because of the poor prognosis for adults with relapsed ALL, investigators assessed the efficacy and safety [ Read More ]

Many Cancer Survivors Have Untreated Depression

Charles Bankhead


Nearly 20% of community-dwelling cancer survivors with depression received no treatment for their depression, according to an analysis of nationally representative data. Among patients whose records included International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) codes associated with depression, [ Read More ]